RxDoctor Payments Data

Sanchita Mandal Singhal, MD

Cardiovascular Disease · Hamilton, NJNPI 1194762591

Payments from drug & device makers

$2,219in general payments, 2019–2025

Across 113 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$742
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$227
  • Johnson & Johnson$198
  • Amgen$194
  • Kestra Medical Technology Services, Inc.$126
  • AstraZeneca$122
  • plus $611 from 11 others

What the payments were for

  • Food & beverage$2,219100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,219 in reported general payments places this provider in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$120,720
Medicare patients
509
Services billed
1,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$34,146
Repatha PushtronexEvolocumab27$22,429
Ezetimibe24$1,945
Rosuvastatin Calcium89$1,681
Valsartan29$824
Metoprolol Succinate39$567
Pravastatin Sodium13$559
Losartan Potassium42$429
Carvedilol32$372
Atorvastatin Calcium60$347
Amlodipine Besylate28$263
Metoprolol Tartrate28$251
Lisinopril14$161
ClopidogrelClopidogrel Bisulfate14$132
Hydralazine Hcl14$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$72$34,14633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Hamilton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →